March 22, 2024
Japan’s health ministry on March 21 granted orphan drug designation to three drugs including Janssen Pharmaceutical’s talquetamab for multiple myeloma (MM). The two other compounds given the orphan status are MSD’s sotatercept (expected indication: pulmonary arterial hypertension) and argenx Japan’s...read more